International Clinical Trial: The Comparison Between Sublingual Administration Of Orally Disintegrating Olanzapine Versus Intravenous Administration Of Metoclopramide For Treatment Of Breakthrough Chemotherapy-Induced Nausea And Vomiting (CINV) In Patients Receiving Chemotherapy

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (TCTR20251008001) titled 'The Comparison Between Sublingual Administration Of Orally Disintegrating Olanzapine Versus Intravenous Administration Of Metoclopramide For Treatment Of Breakthrough Chemotherapy-Induced Nausea And Vomiting (CINV) In Patients Receiving Chemotherapy' on Oct. 8.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University

Condition: Patients with cancer receiving highly or moderately emetogenic chemotherapy who develop breakthrough chemotherapy-induced nausea and vomiting (CINV) despite standard antiemetic prophylaxis. Breakth...